mg, an anticholinergic drug that is relatively selective for the Ml receptor subtype, and bornaprine, 4 mg, a nonselective Ml and M2 antagonist, were administered orally in a randomized, double-blind design to twelve healthy volunteers to investigate the effect on polysomnographically recorded sleep. Both drugs suppressed rapid eye movement (REM) sleep as reflected by an increase of REM latency and a decrease in the KEY WORDS: Bornaprine; Biperiden; Cholinergic system; REM sleep; Slow wave sleep There is strong evidence that the cholinergic system is involved in the generation of rapid eye movement (REM) sleep (Hobson et al. 1986) . Whereas the trigger ing of REM sleep by cholinergic neurons has been demonstrated convincingly (Hobson et al. 1975 (Hobson et al. , 1986 Shiromani et al. 1987) , it is still a question as to the ex tent muscarinic M1 and/or M2 receptors are involved in REM sleep regulation. Results of a recent study based on the microinjection of cholinomimetic drugs at the medial pontine-reticular formation in cats suggest that physiological and cholinergically induced REM sleep is mediated primarily by the M2 subtype of muscarinic receptors (Velazquez-Moctezuma et al. 1989 , 1990 . In comparison, biperiden, a preferential M1 antagonist, increased REM sleep latency, and reduced REM sleep time in healthy volunteers (Gillin et al. 1991; Salin Pascual et al. 1991 .
There is strong evidence that the cholinergic system is involved in the generation of rapid eye movement (REM) sleep (Hobson et al. 1986) . Whereas the trigger ing of REM sleep by cholinergic neurons has been demonstrated convincingly (Hobson et al. 1975 (Hobson et al. , 1986 Shiromani et al. 1987) , it is still a question as to the ex tent muscarinic M1 and/or M2 receptors are involved in REM sleep regulation. Results of a recent study based on the microinjection of cholinomimetic drugs at the medial pontine-reticular formation in cats suggest that physiological and cholinergically induced REM sleep is mediated primarily by the M2 subtype of muscarinic receptors (Velazquez-Moctezuma et al. 1989 , 1990 . In comparison, biperiden, a preferential M1 antagonist, increased REM sleep latency, and reduced REM sleep time in healthy volunteers (Gillin et al. 1991; Salin Pascual et al. 1991 effect of biperiden and bomaprine, two cholinergic an tagonists, on sleep, especially REM sleep, in healthy subjects. The pharmacokinetic properties of both drugs are similar (Hollmann et al. 1984; Grimaldi et al. 1986; Mayo et al. 1980) . Biperiden is considered to be a highly selective M1 antagonist (Burke 1986; Syvalahti et al. 1988; Eltze and Figala 1988; Freedman et al. , 1988) with a M1 selectivity similar to that of pirenzepine (Syvalahti et al. 1987; Avissar and Schreiber 1989; Larson et al. 1991) . Bomaprine, another centrally acting anticholiner gic drug, lacks selectivity for the M1 or M2 receptor hav ing equal affi nity to both receptor subtypes (Kreiskott and Kretschmar 1985) . The antagonism of bomaprine at the M2 muscarinic receptor has been demonstrated (Huff ord et al., 1991) . If M2 receptors are mainly respon sible for the generation of REM sleep, a nonselective anticholinergic drug like bomaprine, that also shows M2 antagonistic properties, should have stronger REM sleep-suppressing effects compared to a preferential M1 receptor antagonist like biperiden.
SUBJECTS AND METHODS
We investigated 12 healthy volunteers with a mean age (±SD) of 25.01 ± 1.9 years (range 22-28 years) who were paid for their services. After one adaptation night, the subjects slept on night 2, night 5, and night 8 in the sleep laboratory. Biperiden, 4 mg, bornaprine, 4 mg, or placebo were given at 9 P.M. (Le., two hours before the lights were turned off) on nights 2, 5, and 8 in a double-blind, randomized way. No sleep EEG record ings were performed in the drug-free nights of 3, 4, 6, and 7, which served to avoid carryover effects of the drugs given on the succeeding nights. Sleep was recorded between 11.00 P.M. and 7.00 A.M. according to standard procedures (Rechtschaffen and Kales 1968) . For descriptive purposes, mean ± SD were calcu lated. To compare placebo and drug conditions, a one way ANOV A for repeated measurements was com puted (df corrected according to the method of Green house-Geisser). For ANOV As yielding a p value < .05, statistical contrasts (two-tailed t-tests) were calculated to compare the three different conditions (placebo, bor naprine, biperiden) with each other.
RESULTS
In the ANOV A, no statistically significant effects con cerning sleep continuity and sleep architecture occurred.
Especially slow wave sleep (SWS) remained unchanged.
Mean ± SD of REM sleep variables and the results of the statistical analysis are depicted in Table 1 .
Concerning a lenient defInition of REM latency (Le., time from sleep onset to the frrst epoch of stage REM), no statistically significant effect as calculated by ANOV A occurred. With a strict defmition of REM latency (Le., NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.1 calculating the interval from the frrst consecutive 10 min of uninterrupted sleep [at least stage 2] to the frrst REM period, which was at least 3 min in length), a significant effect was detected. Calculations of statistical contrasts revealed that bornaprine almost significantly increased REM latency, whereas with biperiden, a significant in crease of REM latency was noted. Further statistically significant effects in the ANOV A occurred for REM per cent sleep period time (SPT), and total REM density (%).
The calculation of contrasts demonstrated that all of these effects were stronger for biperiden, compared to placebo, than for bornaprine, compared to placebo. For REM percent SPT, a highly significant decrease was demonstrated for biperiden, whereas with bornaprine, the level of significance just reached p < .05. The dura tion of the frrst REM period was decreased Significantly only with biperiden. With respect to phasic parameters of REM sleep, a significant increase of REM density of the whole night was noted with biperiden compared to placebo but not with bornaprine.
DISCUSSION
Biperiden, as well as bornaprine, suppressed REM sleep in healthy volunteers. Our results with biperiden are consistent with human pharmalogical (Salin-Pascual et al. 1991; Gillin et al. 1991) and with animal studies (Zol toski et al. 1993) , that demonstrated a dose-dependent suppression of REM sleep following the administration of biperiden. In accordance with animal data (Zoltoski Velazquez-Moctezuma et al. (1989 , 1990 ) based on animal data, the nonselec tive M1 and M2 antagonist bornaprine was supposed to have a stronger REM sleep-suppressing effect com pared with the selective M1 antagonist biperiden. In contrast to this assumption, the M1 antagonist biper iden showed a stronger REM sleep-suppressing effect compared with the nonselective cholinergic antagonist bomaprine. Several explanatory factors should be con sidered.
First, although biperiden is a highly selective M1 antagonist comparable to pirenzepine (Syvhlahti et al. 1987; Avissar and Schreiber 1989) , the drug also has weak antagonistic effects on the M2 receptor. Thus, the possibility cannot totally be eliminated that at higher doses, biperiden may act also on the M2 receptor. Nevertheless, 4 mg of biperiden appear to be a low dose and the REM sleep-supressing effect of the nonselec tive M1/M2 antagonist bornaprine was lower. Restrict ing speculations, comparative studies in animals on the central nervous effect of both drugs are lacking, and we are not aware if both drugs have comparable cen tral nervous activity at the same dose of 4 mg.
Second, as pointed out by Zoltoski et al. (1993) , the hypothesis that REM sleep was triggered by M2 mus carinic receptors arose from studies in which relatively selective muscarinic agonists and antagonists were ap plied to the medial pontine reticular formation (Hob son et al. 1986; Shiromani et al. 1987) . Thus, it might be that other anatomical sites, including those with M1 receptors, can modify or modulate the onset, main te nance, or nature of REM sleep (Zoltoski et al. 1993) .
To summarize, our study confIrms earlier results indicating that antimuscarinic agents suppress REM sleep and increase REM latency. The data, together with the other reported studies, suggest that M1 receptors may also be involved in the regulation of REM sleep in humans. Further studies are needed to clarify the exact functional and anatomical relationship between M1 and M2 receptors in the regulation of REM sleep.
